Home / Prepare Your Business for Sale / Veterinary Practice

How to Prepare Your Veterinary Practice for a Sale or Exit (2026)

Updated April 2026 · CT Acquisitions

Most veterinary practice owners decide to sell, sign with a consolidator, and find out 90 days later that their practice is worth 20% to 30% less than the multiples that were quoted in 2021 and 2022. The PE consolidation lane in veterinary medicine cooled materially after late 2022, the large-platform recapitalization market has been largely dormant since the 2022 VetCor / People, Pets & Vets transaction, and invoice volume has now declined at least 2% per year for four consecutive years (Vetsource Veterinary Analytics, 2025; AVMA, 2025). The AVMA Chief Economist declared the profession in a recessionary period that began November 2024, with possible recovery in Q2 2026 (Frontiers in Veterinary Science, 2025). And yet Ackerman Group still tracked weighted-average GP purchase price multiples at 12.4x in 2H25, with A+ hospitals clearing 14x or higher, while average sub-scale demand-only single-doctor practices compressed back into the 4x to 7x range (Ackerman Group Q4 2025 Update). This guide is the 36-month playbook for owners 6 to 36 months from a corporate or PE exit. Every multiple, every named buyer, and every stat cites its source.

If you are 6 to 36 months from a possible exit, this is the work that determines whether you are an A+ hospital at 14x or an average practice at 7x. On a $2M EBITDA general practice, that is the difference between a $14M sale and a $28M sale. Whether you want to prepare your veterinary practice for a sale to a corporate consolidator like Mission Pet Health or Mars Veterinary Health, prepare your veterinary practice for an exit to a specialty platform like MedVet or VEG, or simply maximize value over the next 1 to 3 years before going to market, the work below applies. The bifurcated 2026 market punishes unprepared sellers and rewards prepared ones more than at any point in the last decade.

What Private Equity Actually Buys in Veterinary Practice (2026)

Corporate consolidators were estimated to control about half of the US veterinary care market by 2021, with 25% of general practices and 75% of specialty practices in corporate hands (AAHA, “Corporate consolidation and the rise of private equity”). Between 2017 and 2023, PE firms spent more than $50 billion in the US vet sector (Ackerman Group). A 2025 Ackerman scan tracked 35+ active corporate veterinary acquirers, the great majority PE-backed. PE buyers accounted for over 60% of pet-sector deal volume in 2024, and PE investors contributed nearly 80% of total capital invested in 2024 (Martilaw Group, “Veterinary Practice M&A Trends in 2025”). The capital is real. But the profile sponsors will pay for has narrowed sharply since 2022, and the profile you build determines the multiple you get.

The PE-attractive veterinary profile

• EBITDA threshold for corporate buyer interest: $500K to $1M EBITDA is the entry band for most regional consolidators. $1M to $3M EBITDA is the sweet spot where multiple PE-backed buyers run a competitive process. $3M+ moves you into a tier where Mission Pet Health, NVA, Mars, VetCor, AmeriVet, and VPP all show up. Above $25M EBITDA you become a platform candidate yourself.
• Associate-driven production: Owner-DVM clinical share below 30% to 40%. Associate DVMs producing 50%+ of clinical revenue. This is the single largest multiple driver in veterinary literature (rightfitcapital 2025; SovDoc 2025; Today’s Veterinary Business). Owner-dependent shops trade at 4x to 7x; associate-driven shops 9x to 13x.
• Wellness plan / recurring revenue: 18%+ of eligible pets enrolled (industry average) with monthly recurring billing, plan-mix, churn, and deferred revenue reported. Above 25% to 30% is premium positioning (IDEXX 2024; Vet Software Hub 2026).
• EBITDA margin: 11% to 12% is the small-practice average; 18%+ is the top quartile that “receives the highest buyout offers” (DVMElite 2026).
• Geography: Suburban Sun Belt, Texas, Florida, the Carolinas, Mountain West growth metros, and dense Northeast suburbs are where 2026 sponsor demand concentrates. Rural single-site practices discount.
• Specialty case mix: 25%+ of revenue from dental, soft-tissue surgery, urgent triage, ultrasound, or exotics lifts both the gross margin and the underlying base multiple (DVMElite 2026; Today’s Veterinary Business).
• DVM and tech retention: 12-month rolling DVM retention above 80% and tech retention above 75%. About 20% of early-career veterinarians leave the profession (Pulivarthi Group 2025) and nearly 30% of the entire workforce is considering leaving in the next 5 years (Mars Veterinary Health 2025; VIN), so a stable bench is a defensible asset.
• Owner role: Owner clinical share dropped to 20% to 30%, practice manager / GM in place 12+ months pre-sale, two-week unplugged owner vacation completed without incident.

Active veterinary PE and corporate platforms in 2026

The list below covers the most active sponsor-backed and strategic veterinary platforms in the 2024 to 2026 cycle. This is who will see your teaser. Hospital counts shift fast and many add-ons go undisclosed; treat counts as directional. Sources include AAHA, AVMA, dvm360, PrivSource, PitchBook, Tracxn, sponsor press releases, and Ackerman Group quarterly market updates.

Additional active platforms named in 2024 to 2026 industry materials but with thinner disclosure: Encore Vet Group; Innovetive Petcare (Audax Private Debt + Metalmark Capital); Heart + Paw; VetEvolve (sold by Align Capital Partners to Varsity Healthcare Partners); Veritas Veterinary Partners (Percheron Capital); Suvetta (Webster Equity Partners); Petfolk (Deerfield Management Series C 2024); Bond Vet and Small Door Veterinary (VC-backed urgent-care concept); Galaxy Vets (employee-owned); Curo Pet Care + MASH; CompletePet (Align Capital).

Add to that list the strategic acquirers. Mars Inc. remains the dominant strategic, adding roughly 180 US clinics in 2025 across VCA, Banfield, and BluePearl (Transitions Elite consolidator scan 2026; Mars Veterinary Health). BluePearl has nearly doubled to about 100 hospitals under Mars ownership (Yahoo Finance, January 2025). JAB Holding Co. owns NVA and Ethos and bought Ethos parent in 2022 for $1.65B (PE Hub June 2022). Chewy (NYSE: CHWY) entered owned-vet-clinic operations in 2023 to 2024 and announced the Modern Animal acquisition in April 2026, scaling Chewy Vet Care from 18 to 47 locations and adding $125M+ run-rate revenue (Chewy investor release April 8, 2026; Businesswire). Goldman Sachs MBD took the lead position in MedVet alongside SkyKnight in February 2025 (Yahoo Finance Feb 2025). Note that the FTC issued consent orders against JAB in 2022 around specialty consolidation, which constrains how aggressively any sponsor can roll up specialty / emergency in any single MSA (FTC press 2022; AVMA news; Lexology).

Veterinary Practice Valuation Multiples in 2026 (What You Are Actually Worth)

The multiple a buyer pays comes down to your size, your associate leverage, your wellness-plan ARR, your specialty case mix, your EBITDA margin, and your geographic fit. Below is the 2026 range, cross-referenced from Ackerman Group quarterly market updates, Transitions Elite Q1 2025, DVMElite 2026, SovDoc 2025, Serenity.vet 2026, First Page Sage 2025, and Peak Business Valuation.

SDE multiples (smaller, owner-operated)

EBITDA multiples (corporate / PE attractive size)

Source: SovDoc 2025; DVMElite 2026; Serenity.vet 2026; First Page Sage 2025; Transitions Elite Q1 2025 (overall transaction range 6x to 16x adjusted EBITDA depending on size, staff stability, and location); Ackerman Group Q4 2025 weighted-average GP at 12.4x with A+ hospitals at 14x+; Mission Pet Health 17x to 18x platform comp per Ackerman Q4 2025.

Compression and bifurcation: Multiples compressed from the 12x to 18x highs of 2021 to a more realistic 8x to 12x by 2023, then partially recovered for top-quartile assets in 2025 even as the average sub-scale GP held flat or drifted lower (Veterinary Practice News “A look at 2024 acquisition market shifts”; rightfitcapital 2025; Ackerman Q4 2025). Estimated peak-to-trough compression on average sub-scale GP practices from 2021 / 2022 to 2024: 20% to 30% (cross-source estimate from Ackerman, Transitions Elite, and Physician Growth Partners winter 2024 update). Specialty and emergency continues to attract the highest multiples in the industry because case mix is higher gross-margin and ER capacity is structurally under-served.

Recent disclosed veterinary transactions (2024 to 2026)

Sources: dvm360 July 2025; Mission Pet Health press July 21, 2025; Transacted; CTOL Digital; Chewy investor release April 8, 2026; Businesswire; MedVet press June 2024; Yahoo Finance Feb 2025; PRNewswire Thrive March 31, 2025; Peloton press July 15, 2024; PrivSource T&D continuation fund; AmeriVet Veterinary Partners blog; Businesswire March 2022.

Estimate flag: most US veterinary single-practice transactions are not disclosed at the per-deal multiple level. The 17x to 18x Mission Pet Health figure is the single most defensible 2024 to 2025 platform-tier data point. Sub-platform multiples should be read as ranges from Ackerman, Transitions Elite, DVMElite, and SovDoc rather than as deal-specific facts.

The 12 Value Levers That Move Your Multiple (Ranked by Impact)

These are the levers that move veterinary multiples in the 24 months before a sale. Each one has a current state, a target state, and an estimated financial impact. The ordering is by dollar impact per unit of effort, based on cross-source synthesis from Ackerman Group, SovDoc 2025, Serenity.vet 2026, DVMElite 2026, rightfitcapital 2025, Today’s Veterinary Business, IDEXX, Provet, and Mars Veterinary Health.

Lever 1: Drop owner-DVM clinical revenue share to under 30%

Current: Owner-DVM produces 50% to 70% of clinical revenue and supervises all major cases. Target: Associate DVMs produce 50%+ of revenue; owner clinical share drops to 20% to 30%; owner clinical days drop from 5 to 2 or 3 per week. Impact: Owner-dependence is the single most-cited multiple compressor in veterinary literature. Practices with 50%+ associate-driven revenue trade at 9x to 13x; practices where revenue is concentrated on the owner-DVM trade at 4x to 7x (rightfitcapital 2025; SovDoc 2025; Serenity.vet 2026). On a $1.5M EBITDA practice that delta is the difference between an $8M to $10M sale and a $14M to $18M sale. How: Hire 1 to 2 associate DVMs 18 to 24 months pre-sale; build production-based ProSal comp; transfer top-tier client relationships to associates by name; document the owner step-down inside the operating model.

Lever 2: Build wellness plan / preventive-care membership penetration to 18%+

Current: Under 10% of eligible pets on wellness plans; no monthly recurring revenue line. Target: 18%+ of eligible pets enrolled (industry average per IDEXX 2024), or 30%+ for premium positioning; monthly recurring revenue explicitly reported and growing. Impact: Wellness plans drive higher visit compliance (member pets visit 1.5x to 2x more often per IDEXX 2024 ROI study), higher ACT through dental and diagnostic adherence, and a deferred revenue line that demonstrates predictable cash flow. Estimate +0.5x to 1.0x multiple uplift, plus the underlying ARR-growth uplift to EBITDA itself (IDEXX 2024; Provet 2026; Vet Software Hub 2026). How: Adopt a wellness-plan platform (Pulse Membership, Pet360, Vetsource Wellness Plans, PetDesk Care Plans, Stride). Train every DVM and tech to present at puppy / kitten and senior visits. Tier the plans (Basic, Plus, Senior, Dental).

Lever 3: Lift average client transaction (ACT) and exam volume per DVM

Current: ACT $185 to $220 (national average); 3,200 to 4,000 invoices per DVM per year; flat year over year (NectarVet 2025; Provet 2026). Target: ACT $300 to $400+; 4,000 to 4,800 invoices per DVM; 5% to 8% annual price increase held without volume cliff. Impact: Direct EBITDA growth. A 10% ACT lift on 8,000 transactions adds $150K+ revenue per year, and at vet gross margins of 60% to 75% on professional services that drops most of the way to EBITDA (Provet 2026; Weave benchmarks). At a 10x EBITDA multiple, $100K of EBITDA lift adds $1M to sale price. How: Quarterly fee schedule review; dental compliance push (the highest-margin under-used service line); diagnostic bundle protocols on senior wellness (CBC / Chem / UA / T4 as a standing senior workup); flat-rate published estimates; tech-driven pre-op compliance.

Lever 4: Shift case mix toward specialty (dental, surgery, urgent triage, ultrasound)

Current: 60% to 70% vaccines + wellness; under 10% dental; under 10% surgery; under 5% other specialty. Target: 30% to 40% specialty (dental, soft-tissue surgery, urgent triage, ultrasound, exotics). Impact: Specialty case mix runs at 60% to 75% gross margin vs. vaccines at 40% to 55%. Shifting mix 10 points lifts blended gross margin by 3 to 6 points, which on a $2M revenue practice is $60K to $120K of EBITDA. At a 10x multiple, $600K to $1.2M of additional sale price. Plus specialty positioning supports a higher base multiple (DVMElite 2026; Today’s Veterinary Business). How: Add a dental specialist or contract surgeon part-time; invest in dental X-ray; build a triage protocol for urgent-care walk-ins; add ultrasound; add exotics if local market supports.

Lever 5: Migrate to cloud PIMS and run a real monthly close

Current: Server-based AVImark or Cornerstone or paper records; KPIs anecdotal; monthly close 30 to 45 days. Target: Cloud PIMS (ezyVet, Vetspire, Pulse by IDEXX, Provet Cloud, NaVetor, Hippo); real KPI dashboard covering ACT, invoices per DVM, new clients per month, compliance rate, wellness plan member count, controlled-substance log, gross margin by service line; monthly close in 15 days. Impact: Estimated +0.25x to 0.75x multiple uplift, primarily driven by data-room speed and KPI defensibility during diligence. Avoids the integration risk discount PE buyers apply to practices still running legacy server software (Vet Software Hub 2026; Today’s Veterinary Practice). Cloud PIMS also enables wellness plan automation, telehealth integration where state-legal, and online booking that drives new-client growth. How: 24+ months out, scope a migration; budget $20K to $80K plus ongoing per-user license; train clinical and front-desk team; force adoption with payroll-tied closure compliance.

Lever 6: Lock in associate DVM and credentialed tech retention

Current: 25%+ DVM and tech turnover; no career ladder; non-competes either unenforceable or never signed. Target: Under 15% DVM turnover; under 20% tech turnover; documented ProSal + bonus structure; signing bonuses; CE budgets; documented career ladder (assistant > kennel tech > vet assistant > credentialed tech > lead tech > practice manager). Impact: Replacing a vet costs 100% to 150% of salary (Mars Veterinary Health 2025; Pulivarthi Group 2025). On a 3-DVM practice with one associate departure post-LOI, the buyer may price in 0.5x to 1.0x multiple haircut or push for an escrow tied to associate retention milestones. Industry context: ~14,300 vet tech openings annually vs. ~7,500 new credentialed grads (Bureau of Labor Statistics via Vet Tech Colleges 2025); any practice retaining techs above 80% for 24 months has a defensible asset. How: Pay at or above regional role-specific market; pay for credentialed-tech upskilling; offer a written associate buy-in or future ownership track; sign non-compete / non-solicit per state law where enforceable.

Lever 7: Earn AAHA accreditation

Current: Not accredited (85% of US small-animal practices are not accredited per AAHA). Target: AAHA accredited. Impact: “Accredited practices typically command higher values” (AAHA Newstat 2023; NAHF 2024). Estimated +0.25x to 0.5x multiple uplift, plus the operational hygiene that translates into smoother diligence. AAHA accreditation does not auto-transfer at sale; the corporate buyer must maintain compliance, so the practical impact is reputational, KPI evidence, and the visit-by-visit operational discipline AAHA enforces. How: 12 to 24 month process; budget $4K to $8K initial fee plus ongoing renewals; allocate a manager to drive the standards-by-standard checklist.

Lever 8: EBITDA add-back hygiene and owner compensation reset

Current: Owner takes $200K to $400K salary; commingles personal expenses; no add-back log. Target: Owner takes documented market-rate associate-DVM equivalent salary plus a separate manager-equivalent comp; every personal item flagged as add-back live; related-party rent at FMV with rent study on file. Impact: Every defensible dollar of adjusted EBITDA is multiplied. At a 10x multiple, $100K of clean add-backs equals $1M of sale price (Today’s Veterinary Business “Using EBITDA”; SovDoc 2025; Serenity.vet 2026; Ackerman “Normalized EBITDA Explained”). For veterinary specifically, the owner-DVM-as-clinician plus owner-as-manager double-replacement is the largest single add-back line. Industry guidance: appraisers substitute owner’s salary with the cost of an associate at similar production plus a manager. How: Adopt a monthly add-back log starting today. Document business purpose of every charge. Get a FMV rent appraisal if owner owns the building. Replace owner-family payroll for non-functional roles.

Lever 9: Working capital normalization and wellness-plan deferred revenue isolation

Current: Wildly seasonal A/R; no inventory discipline; prepaid wellness plan liability mixed in with ordinary deferred revenue; drug + food + retail inventory turn slow. Target: TTM-average working capital stable and predictable; deferred wellness plan revenue on a separate balance sheet line; drug + retail inventory under 60 day turn. Impact: Working capital peg set off TTM average per BDO and Morgan & Westfield NWC guides. A volatile pattern lets the buyer set a higher peg, which subtracts from purchase price. Vet-specific issue: prepaid wellness-plan liability is sometimes contested as a debt-like item rather than ordinary working capital and can come out of price entirely. Estimated impact: 1% to 3% of enterprise value at close. How: Tighten A/R collection; manage drug + food + retail inventory; isolate deferred wellness revenue on the GL.

Lever 10: Real estate decision (own, lease, or sale-leaseback)

Current: Owner-occupied real estate held in same entity as operating practice, or in a sister LLC at above-FMV rent. Target: Real estate in a separate LLC at FMV NNN lease (typically $25 to $45 PSF for purpose-built veterinary in metro markets, per cross-source commercial brokerage data) with a clear path for buyer either assuming the lease or buying the real estate. Impact: Separating real estate often lifts the implied EBITDA multiple on the operating practice because the buyer is not forced to underwrite real estate exposure (Plante Moran sale-leaseback primer; Northmarq guide; W. P. Carey blog). A sale-leaseback can free up close to 100% of property market value as cash vs. 70% to 80% LTV traditional refinancing. Estimated impact: holding real estate separately at FMV adds 0.5x to 1.0x to the operating multiple, and a sale-leaseback at attractive cap rates (typically 6.5% to 8% for veterinary medical office) can monetize the real estate at a separate transaction. How: Get a FMV market-rent study now; restruck rent if needed; decide pre-marketing whether real estate is part of the deal or held back.

Lever 11: Marketing diversification, online booking, and recall discipline

Current: 60%+ of new clients from owner relationships and word of mouth; under 4.0 Google rating; under 100 reviews; no PetDesk or Vetstoria online booking; no email or SMS recall. Target: Under 30% from owner relationships; 4.5+ Google rating with 300+ reviews; online booking via PetDesk, Vetstoria, or PIMS-native; documented client recall system at 80%+ on annual exam reminders; basic SEO + LSA. Impact: Concentrated lead source through the owner is key-person risk by another name. Diversified, trackable acquisition is what makes the demand engine transferable in the buyer’s underwriting. Estimated +0.25x to 0.5x multiple in consumer-driven markets. Also drives top-line growth that compounds into EBITDA. How: Branded post-visit SMS review request flow; online booking; recall via PIMS-native tools; LSA + Google Ads under a marketing manager, not the owner.

Lever 12: Compliance scrub (DEA, state board, OSHA, USDA, controlled substances, X-ray)

Current: DEA registration in owner-DVM name; controlled-substance log in a paper binder; no annual OSHA training documentation; X-ray registration uncertain; chemo SOPs informal. Target: Every operating registration current; controlled-substance log digital with daily reconciliations and biennial inventory; OSHA Bloodborne Pathogens + Hazardous Drugs training documented annually; X-ray unit registered with the state radiation control program; expired-drug disposal contracted with a reverse distributor; AAHA standards in active use. Impact: Each of these can kill or re-trade the deal at confirmatory diligence. See the deal-killer section below for specifics. How: Cover this in months 24 to 12 of the run-up, before the QoE.

What PE Asks Before They Send an LOI (The Pre-LOI Diligence Stack)

Before a corporate or PE buyer commits to a letter of intent, they ask for a focused diligence package. The list below is the standard pre-LOI ask from a 2026 veterinary consolidator. The “why” and “how to prepare” expand each item to what is typical across the industry. Sell process flow: Confidential Practice Valuation > Teaser > NDA > CIM > IOI > Management Meeting / Hospital Tour > LOI with exclusivity > Confirmatory DD > Definitive Purchase Agreement (typically Asset Purchase Agreement, since 90%+ of vet transactions are asset purchases) > Close (Ackerman Group “10 Steps in Every Vet Practice Sale”; VP Veterinary Advisors roadmap; Acquisition Stars 2026 Guide).

1. Income Statements for 2024, 2025, and the latest trailing twelve months

Why PE asks: They are building the LTM EBITDA they will multiply. They want trend (growth rate, margin trajectory), seasonality, and the service-line mix (professional services vs. vaccines vs. dental vs. surgery vs. boarding vs. grooming vs. food and pharmacy). LTM is the bridge between the most recent year-end and today, so the headline price reflects current run-rate, not stale data. In 2026 the buyer is especially focused on whether revenue growth is volume-driven or price-driven; price-only growth on declining patient visits is the current industry red flag (Ackerman Q4 2025; Serenity.vet 2026).

How to prepare: Accrual-basis P&L by month, mapped to a clean veterinary chart of accounts. Service-line P&L (professional services, vaccines, dental, surgery, boarding, grooming, food + pharmacy). Reconcile to tax returns so there are no surprises in confirmatory diligence.

2. Balance sheet at the latest month

Why PE asks: Two reasons. First, to start sizing the working capital peg they will set in the purchase agreement. Second, to identify net debt and debt-like items. For vets, the deferred revenue line on prepaid wellness plans (Banfield Optimum-style or independent equivalents) is the most commonly negotiated debt-like item, along with unredeemed bath / grooming packages and prepaid boarding deposits. Both peg and net debt come out of the purchase price.

How to prepare: Tie balance sheet to trial balance; segregate prepaid wellness plan liability; reconcile drug + food + retail inventory to physical count.

3. Adjusted EBITDA bridge with add-back documentation

Why PE asks: Sneak peek at how clean the EBITDA story will hold up. Aggressive or undocumented add-backs trigger discounted multiples and bigger working capital escrows.

How to prepare: Build the bridge from book EBITDA to adjusted EBITDA, line by line. Document every add-back with the underlying invoice or payroll record. Common veterinary add-backs that hold up: owner-DVM compensation above market-rate associate replacement cost (appraisers substitute owner’s salary with the cost of an associate at similar production plus a manager per SovDoc 2025; Today’s Veterinary Business “What’s the deal with EBITDA”; Serenity.vet 2026); owner-family payroll for non-functional roles; related-party rent above FMV (added back to the FMV delta with rent study on file); one-time legal fees; PIMS migration and build-out costs; owner vehicle and personal CE travel above industry norm; owner health insurance; COVID-era ERC / PPP forgiveness one-time items.

4. Anonymized employee roster (titles, license numbers, start dates, pay structure)

Why PE asks: Two risks. First, DVM tenure vs. industry attrition. About 20% of early-career veterinarians leave the profession (Pulivarthi Group 2025); nearly 30% of the entire veterinary workforce is considering leaving in the next 5 years (Mars Veterinary Health 2025; VIN). Buyer wants to see if the associate DVM bench is stable. Second, owner-DVM concentration. If the owner produces 50%+ of revenue, that is key-person risk that hits the multiple.

How to prepare: Roster columns should include role (DVM, RVT / CVT, vet assistant, receptionist, manager, kennel), license number plus state plus expiration, hire date, FTE %, W-2 vs. 1099 with classification rationale, comp structure (base, ProSal / production, bonus, spiff), and any active non-compete / non-solicit with state and term. Calculate and disclose 12-month and 24-month rolling DVM and tech retention.

5. Revenue breakdown and average client transaction (ACT) by service mix

Why PE asks: This is the single most diagnostic exhibit. It tells them whether the practice is dental + surgery + diagnostics heavy (higher margin) or vaccines + retail heavy (lower margin); whether ACT is trending up, flat, or declining (a flat or declining ticket is a pricing-discipline red flag); and whether revenue growth is volume vs. price. In 2026 buyer scrutiny increased materially on the volume-vs-price question because industry visits are down 2.3% year over year and revenue is up 3.9% on price (AVMA price sensitivity 2025; Serenity.vet 2026).

How to prepare: Pull it straight from PIMS (Cornerstone, AVImark, ezyVet, Pulse, Vetspire, Provet, NaVetor, ImproMed). Benchmarks: ACT $185 to $220 national average; top practices $400+ per visit (Provet 2026; NectarVet 2025). Revenue per FTE DVM $530K to $600K typical; $600K+ premium (Today’s Veterinary Business; Weave; SVA CPA 2025). Invoices per DVM 4,000 to 4,800 annually (Provet 2026). New clients per DVM 25 to 30 per month healthy (Provet 2026).

6. Wellness plan and recurring revenue snapshot

Why PE asks: Recurring monthly billing from wellness plans is the cleanest predictability signal in vet, equivalent to maintenance contracts in HVAC. Buyer wants member count, monthly ARR, churn, plan-mix, average revenue per member, and the deferred revenue liability on the balance sheet from prepaid annual plans.

How to prepare: Member count by month for the last 36 months. Plan-mix breakdown (basic preventive vs. premium with dental). Monthly recurring revenue. Annual renewal rate. Lifetime visit count per member. Industry context: wellness plan adoption in the US is over 18% of eligible pets (IDEXX 2024; Vet Software Hub 2026).

7. Customer / client concentration

Why PE asks: Vet practices rarely have client concentration at corporate-buyer levels, but breed-specific clinics, working-dog contracts (police, military, sled, herd), or animal-shelter contracts can create concentration. Any single client (commercial breeder, rescue, racing operation, university) above 5% of revenue surfaces in DD.

How to prepare: Top 25 client list with revenue contribution, plus a separate list of any institutional or commercial accounts with contract terms summarized.

8. Five-year business plan

Why PE asks: Corporate buyers underwrite years 1 through 5 post-close. They want capacity assumptions (DVM hires, exam-room turnover, hours of operation), pricing actions, and service-line additions (urgent care, dental specialist, mobile services, ultrasound, exotics). Your plan tells them whether you understand your own levers.

How to prepare: A simple operating model: revenue by service line, gross margin assumptions, overhead growth, EBITDA. Include capacity build (DVMs, techs, exam rooms), planned expansion territories or service lines, pricing actions, and any de novo or second-site pipeline.

9. Equipment / capex list and real estate summary

Why PE asks: Three reasons. Replacement capex modeling (digital X-ray, dental units, IDEXX in-house labs, monitors, anesthesia, ultrasound have 5 to 10 year useful lives). Owned vs. leased vs. financed equipment (financed equipment is debt-like and comes out of purchase price). Real estate ownership and lease assignability.

How to prepare: Equipment register (asset, manufacturer, year, condition, financed or owned, lease residual). Real estate: separate LLC vs. operating co. Lease abstract with change-of-control language flagged. Flag any equipment with title or financing issues.

10. Legal and regulatory history

Why PE asks: Vet practices are professional-licensed entities with multiple overlapping regulators: state veterinary medical board (license, complaints, board orders), DEA registration (Schedules II to V controlled substances), USDA APHIS (Class B / C facility license for breeders, dealers, exhibition), state department of agriculture, OSHA, EPA (medical waste, RCRA), state pharmacy boards (some states require separate pharmacy license to dispense compounded drugs).

How to prepare: State board search per operating jurisdiction; DEA registration certificate (current, ideally in business name not just individual DVM); USDA license if applicable; OSHA 300 logs (5-year); EPA / state medical waste vendor contracts; pharmacy license; any open complaints or settlements.

Confirmatory Diligence (After You Sign the LOI)

Once an LOI is signed and exclusivity begins (typically 60 to 90 days per Acquisition Stars 2026 Guide; some PE-backed deals push 90+ days), the buyer runs parallel workstreams. This is the depth of inspection your practice will undergo. If anything was hiding, it surfaces here.

1. Quality of Earnings (QoE). Outside accounting firm runs revenue cut-off testing, deferred wellness-plan revenue analysis, expense normalization, add-back validation, working capital trends. Buyer’s QoE cost: $50K to $250K typical for $1M to $10M EBITDA practice. Output: an adjusted EBITDA number the buyer locks into the model.
2. Customer / caseload analysis. ACT trend, repeat-visit rate, wellness-plan churn, top-25 client review, retention cohort analysis. Often the first place re-trades happen if visits are declining materially during the diligence window (Ackerman Q4 2025).
3. IT systems audit. PIMS data quality, exportability, integration with the corporate platform’s stack. Buyers usually want acquired practices migrated to the platform’s standard PIMS (Cornerstone, ezyVet, Vetspire). Buyer evaluates clean migration risk on patient records, controlled-substance log, and recurring-revenue flags.
4. Legal. Entity good standing in every operating state; state veterinary license per operating state; DEA registration transferability; contracts assignment (lease, equipment, vendor IDEXX / Antech / Heska); litigation (active + threatened including board complaints); warranty and post-op callback liability; malpractice insurance history.
5. HR / Payroll. W-2 vs. 1099 audit (relief DVMs are often paid 1099 but operate like W-2, which surfaces under SS-8 testing); I-9 compliance; wage-and-hour for techs and assistants (overtime classification for kennel staff and after-hours techs is a recurring exposure); benefits; PTO accrual; pending EEOC; non-compete enforceability per operating state.
6. Environmental. Medical waste, sharps, expired-drug disposal records, RCRA compliance, X-ray equipment registration with state radiation control program, USDA Class C if applicable, formaldehyde / chemo handling records for OSHA Hazardous Drugs standard.
7. Tax. Federal income, payroll, sales tax (food and retail sales are taxable in nearly every state; some states tax veterinary services or boarding; the 50-state matrix is the recurring exposure), property tax.

Why You Should Pay for Your Own Quality of Earnings Before Going to Market

A sell-side QoE is your own outside accountant’s QoE, paid for by you, before you go to market. It does three things: pre-empts the buyer’s QoE by getting to the adjusted EBITDA number first with documentation; surfaces issues you can fix before the buyer sees them (revenue recognition on wellness plans, working capital, add-back documentation, deferred revenue treatment); tightens the EBITDA number you take to market, which directly drives the headline price.

Cost

• $25K to $35K for QoE if revenue is below $10M (Eton Venture Services 2025; Morgan & Westfield).
• $35K to $75K typical range for a sell-side QoE on a healthy multi-DVM veterinary practice (synthesis from Kahn Litwin Renza, Eton 2025, Midstreet).
• Up to $150K for practices with complex add-backs, multiple entities, wellness-plan deferred revenue complications, or messy historical books (Eton 2025).

Estimate flag: there is no single veterinary-specific QoE price quote in published materials. The above is synthesized from QoE provider content adjusted upward modestly for the wellness-plan deferred-revenue complexity that buyer-side QoE firms have flagged as the most-negotiated vet-specific accounting issue.

ROI

Standard QoE provider example: $25M revenue, $5M EBITDA business. Moving the multiple from 11x to 12x equals $5M additional sale price. A $50K QoE that supports the 1x lift is a 100x return (Eton “Quality of Earnings Report Cost”, 2025). Veterinary-specific example: $4M revenue practice, $700K reported EBITDA on tax returns, QoE-adjusted EBITDA at $850K after associate-replacement and FMV-rent adjustments. At a 10x multiple the QoE adjustment alone delivers $1.5M additional sale price for a $50K spend (cross-source synthesis; flag as estimate).

Deal-Killers That Re-Trade Veterinary Transactions (Avoid These)

These are the recurring kill-shots cited across veterinary M&A advisory content and confirmatory diligence checklists. Most are fixable in 12 to 24 months. None are fixable in 30 days.

1. Owner-DVM produces too much of the clinical revenue

Owner-DVM producing 50%+ of clinical revenue is the most common vet-specific deal-killer (rightfitcapital 2025; Today’s Veterinary Business). Buyer either prices in a major haircut (1x to 3x multiple), requires a long post-close employment commitment with claw-back, or walks. Owner clinical share above 60% often kills corporate buyer interest entirely below the platform tier.

2. Declining patient visits during the diligence window

The single most common reason for a re-trade in 2025 per Ackerman Group Q4 2025: practices whose visit volume softens between LOI signing and closing. Buyer reopens valuation, often with a 0.5x to 1.0x multiple haircut. Industry-wide invoice volume has declined at least 2% per year for four straight years (Vetsource; AVMA), so this is structural, not bad luck. Mitigation: lock in the trailing twelve months that look strongest, run the process before a soft quarter, and prepare a defensible narrative.

3. Associate DVM non-compete weakness (state-by-state)

Associate non-compete enforceability is state-by-state. Broadly unenforceable: California, Oklahoma, North Dakota, Minnesota (2023 ban). Limited enforceability: Massachusetts (Garden Leave required), Washington (income floor and notice rules), Colorado, Illinois, Virginia. Reasonable enforcement: Texas, Florida, Georgia, Tennessee, North Carolina, Indiana (Mandelbaum Barrett PC; AVMA news; Chelle Law; Squire Patton Boggs). Important update: the FTC vacated its 2024 noncompete rule on September 5, 2025; the FTC now pursues case-by-case enforcement and sent letters to large healthcare employers in September 2025 warning that overbroad noncompetes will draw scrutiny (AVMA, Jenner & Block, APTA 2025). Practical buyer test: if your top associate DVMs have non-competes that won’t hold up in your state (or were never signed), the buyer treats them as flight risks and prices in 0.5x to 1.0x multiple haircut.

4. DEA registration not transferable plus controlled-substance log gaps

DEA registration belongs to the individual DVM, not the facility (Today’s Veterinary Business 2024; Titan Group DEA 2024; SafetyVet). If the seller-DVM is the sole DEA registrant, the buyer must have a new registrant in place at closing or controlled substances cannot continue to flow. Schedule II transfers require DEA Form 222; Schedules III to V require a signed written transfer record by both registrants (21 CFR Part 1301). Any post-close DEA inspection triggered by improper transfer creates joint exposure for buyer and seller. Controlled-substance log gaps (missing daily reconciliation, no biennial inventory, no Form 222s on file) are the single most common DEA finding and a top re-trade item.

5. State veterinary license and CPVM / qualifier structuring issues

Most states require a license-holder DVM to qualify the practice. Corporate practice of veterinary medicine (CPVM) rules vary by state. Some states (CA, NY, NJ, TX with limits) restrict who can own a veterinary practice and require structuring through a professional entity (PC, PLLC, PA) with DVM ownership. Corporate buyers usually structure through a Management Services Organization (MSO) plus friendly-DVM PC; the deal will not close until that structure is approved by the buyer’s regulatory counsel and the state board (AAHA corporate-sale guidance; DM Counsel; Mahan Law).

6. PIMS data quality and exportability

AVImark and Cornerstone on-prem deployments often have years of accumulated dirty data (duplicate client records, miscoded services, no flag for wellness plan members, controlled-substance entries scattered). Buyer’s IT diligence surfaces this and prices integration risk into the deal (Vet Software Hub 2026; Today’s Veterinary Practice). ezyVet, Vetspire, and Pulse cloud platforms generally export cleaner.

7. W-2 vs. 1099 misclassification (relief DVMs and tech support)

Relief DVMs are sometimes paid 1099 but operate like W-2 (set schedules, supplied equipment, exclusive engagement). Misclassification triggers payroll-tax liability $10K to $100K+ per misclassified worker once back taxes, penalties, interest, and legal cost are aggregated (Tax1099; ADP SPARK 2023; IRIS 2025). DOL and IRS enforcement renewed in 2025. Any single SS-8 filing by a former contractor opens an audit.

8. Sales / use tax exposure on retail, food, boarding, and certain services

Most states tax food, retail, and OTC product sales (pet food, supplements, flea / tick, toys). Some states (Texas, Pennsylvania, others) tax some categories of veterinary professional services, boarding, or grooming. The 50-state matrix is the recurring exposure. Buyer’s confirmatory tax DD surfaces multi-year exposure that comes out of purchase price as a holdback or escrow.

9. Real estate lease change-of-control / assignment

Veterinary practices commonly lease purpose-built space. Many medical-office leases require landlord consent on change of control; some require a landlord consent fee or rent reset. Asset purchase often triggers consent. Lease assignment failure delays close or kills the deal (DM Counsel 2025; Real Estate Law Corporation; Mahan Law).

10. OSHA Hazardous Drugs and Bloodborne Pathogens compliance

OSHA’s Bloodborne Pathogens Standard (29 CFR 1910.1030) applies to vet practices because of exposure to animal blood and body fluids. Required: written Exposure Control Plan, PPE, Hepatitis B vaccination offer, annual training; fines start at $15K+ per violation (Gamma Compliance 2024; Oregon VMA). OSHA also follows NIOSH hazardous-drug guidelines for chemo and other hazardous drug compounding and administration; NIOSH specifically lists vet care workers (OSHA Controlling Occupational Exposure to Hazardous Drugs). Missing documentation surfaces in HR DD.

11. State radiation control / X-ray registration plus USDA APHIS Class B / C (when applicable)

X-ray units must be registered with the state radiation control program (separate from FDA equipment registration). Annual fees and periodic inspections. Lapsed registration triggers state board action. Practices that breed, exhibit, or deal in research animals must hold USDA Animal Welfare Act licenses; most companion-animal practices are exempt, but mixed-practice operations with exotic exhibition or research relationships need to disclose and prove license currency (AVMA federal regulation; USDA APHIS).

12. Undisclosed regulatory complaints, board orders, or equipment financing balances

State veterinary medical board complaints (open or recently closed) are discoverable by buyer counsel through public board searches. Anything not disclosed in the seller’s reps is an instant trust problem. Separately, IDEXX in-house labs, digital X-ray, ultrasound, dental units, and PIMS workstations are frequently financed; outstanding balances are debt-like and come out of purchase price.

The 36-Month Exit Prep Timeline

T-36 months: Cleanup phase

• Switch to accrual basis if still on cash basis
• Migrate to cloud PIMS (ezyVet, Vetspire, Pulse by IDEXX, Provet Cloud, NaVetor) if still on AVImark or paper
• Start tagging every potential EBITDA add-back as it happens
• Conduct W-2 / 1099 audit; reclassify relief DVMs if needed; settle exposure now while it is small
• Restruck related-party rent to FMV with appraisal
• Build the org chart and identify the GM / practice manager hire (internal promotion target or external recruit)
• Phase I ESA on any owned real estate
• Single-state (or 50-state if multi-state) sales / use tax compliance review by outside counsel
• Move controlled-substance log to digital reconciliation; verify DEA Form 222s on file
• Get a FMV market-rent study if owner owns the building
• Begin AAHA accreditation process (12 to 24 month timeline)

T-24 months: Financial discipline and KPI infrastructure

• GM / practice manager onboarded and starting to take operational load; owner clinical days drop to 3 to 4 per week
• Monthly close in 15 days; service-line P&L every month
• KPI dashboard: ACT, invoices per DVM, new clients per DVM per month, dental compliance rate, senior wellness compliance, wellness plan member count, plan churn, retention rate, gross margin by service line
• Launch wellness plan if penetration is under 10%; push toward 18%+
• Pricing review: 5% to 8% list increase, documented rationale
• Hire 1 to 2 associate DVMs if owner clinical share is still above 40%
• Build the add-back bridge as a living document
• Restruck non-compete / non-solicit language for associates per state law where enforceable
• Begin specialty case-mix push (dental, surgery, urgent care)

T-12 months: QoE-ready close discipline, eliminate owner dependence

• Owner clinical share drops to 20% to 30%; GM runs daily operations
• Owner takes a 2-week unplugged vacation as the stress test
• Run the sell-side QoE (budget $35K to $75K)
• Tighten balance sheet: clean A/R, kill dormant drug + food + retail inventory, isolate prepaid wellness deferred revenue on the GL
• Final compliance scrub (DEA, state board, OSHA Bloodborne + Hazardous Drugs, X-ray registration, USDA if applicable, sales tax, environmental)
• AAHA accreditation completed
• Lock in 12 months of clean service-line P&L for the CIM
• Document that associate non-competes are signed, current, and enforceable per state

T-6 months: Pre-marketing prep

• Engage M&A advisor (veterinary-specialist sell-side broker or banker). Typical broker fee: up to 10% of sale proceeds on smaller deals (Veterinary Practice News 2024). Banker fee for $5M+ deals: $25K to $75K monthly retainer credited against 4% to 8% success fee
• CIM drafted from QoE + operating model
• Anonymized teaser drafted
• Buyer list finalized, segmented by tier (CT Acquisitions veterinary PE map identifies 25+ targeted buyers across strategic, mid-market PE, specialty / emergency, tech-forward, and regional rollups)
• Virtual data room populated with everything from the pre-LOI and confirmatory sections above
• Management presentation deck built and rehearsed

T-3 months: Go to market

• Teaser distributed; NDAs collected; CIMs distributed
• IOIs collected 2 to 3 weeks after CIM goes out
• Narrow to 4 to 6 finalists for hospital tour / management meetings
• Management meetings; LOIs solicited
• Select LOI; sign with exclusivity (60 to 90 days typical per Acquisition Stars 2026 Guide; Ackerman)
• Enter confirmatory diligence; close

End-to-end from engagement to close: 6 to 12 months in a well-run vet process, with buyer outreach to LOI typically 6 to 8 weeks and diligence to closing 12 to 20 weeks (Acquisition Stars 2026 Guide; Ackerman Group; CVMA roadmap).

Frequently Asked Questions

How long should I plan for before selling my veterinary practice to a corporate or private equity buyer?

The owners who get top-quartile pricing start preparing 24 to 36 months before going to market. The minimum useful prep window is 12 months, because most of the high-leverage levers (dropping owner-DVM clinical share to under 30%, lifting wellness plan penetration to 18%+, migrating off AVImark to cloud PIMS, hiring associate DVMs, completing AAHA accreditation, and running a sell-side QoE) need 12+ months of clean trailing-twelve-months data to be credible to a corporate buyer. Owners who try to sell in under 6 months in the 2026 bifurcated market typically leave 20% to 30% of enterprise value on the table compared to the same practice prepared properly.

What is a realistic EBITDA multiple for a $1.5M EBITDA general-practice vet hospital in 2026?

For a general-practice veterinary hospital at $1.5M EBITDA in 2026, the range is 9x to 11.5x (SovDoc 2025; DVMElite 2026; Serenity.vet 2026). The bottom of that range applies to owner-dependent practices with under 10% wellness-plan penetration, server-based AVImark, no AAHA accreditation, and rural geography. The top applies to practices with 50%+ associate-driven production, 18%+ wellness-plan penetration, cloud PIMS, AAHA accreditation, and a suburban Sun Belt growth market. Ackerman Group tracked weighted-average GP at 12.4x in 2H25 with A+ hospitals at 14x+ (Ackerman Q4 2025 Update). For specialty / emergency at the same $1.5M EBITDA level, the range shifts to 11x to 14x. The 36-month prep playbook moves you from the bottom of the band to the top.

Should I get a quality of earnings report done before going to market?

For veterinary practices at $1M+ EBITDA, yes. A sell-side QoE costs $35K to $75K typical, up to $150K for complex add-back situations (Eton Venture Services 2025). The ROI is leverage. If your QoE supports a 1x multiple uplift on a $1.5M EBITDA practice at a 10x baseline, that is $1.5M of additional sale price for a $50K investment. More importantly, a pre-market QoE surfaces wellness-plan revenue recognition issues, deferred revenue classification disputes, working capital surprises, and add-back weaknesses while you can still fix them, rather than during exclusivity when the buyer re-trades the deal. The wellness-plan deferred-revenue line is the single most-negotiated vet-specific accounting issue and the place a pre-market QoE pays for itself first.

How much of my clinical revenue should be coming from associates instead of me before I sell?

Associate DVMs should produce 50%+ of clinical revenue, with owner clinical share dropped to 20% to 30%, ideally 12+ months pre-sale. Owner-dependence is the single most-cited multiple compressor in veterinary literature (rightfitcapital 2025; SovDoc 2025; Serenity.vet 2026). Practices with 50%+ associate-driven revenue trade at 9x to 13x; practices where revenue is concentrated on the owner-DVM trade at 4x to 7x. On a $1.5M EBITDA practice, that delta is the difference between an $8M to $10M sale and a $14M to $18M sale. Hire 1 to 2 associate DVMs 18 to 24 months pre-sale on production-based ProSal, transfer top-tier client relationships by name, and document the owner step-down inside the operating model the buyer sees.

Will the corporate buyer keep my associate DVMs and tech team after they buy my practice?

In most corporate acquisitions, yes, retaining the existing DVM and tech team is the buyer’s preferred outcome because the vet workforce shortage makes replacement expensive (about 20% of early-career veterinarians leave the profession per Pulivarthi Group 2025; nearly 30% of the entire workforce is considering leaving in the next 5 years per Mars Veterinary Health 2025). Buyers will typically extend offer letters at or near current comp, sometimes with signing bonuses, and they will require the seller to use commercially reasonable efforts to support the transition. The risk is that associates leave post-LOI before close, which can trigger a re-trade or escrow. Mitigate by: signing enforceable non-competes pre-sale where state law allows; locking in 12-month rolling retention above 80%; involving key associates in the management presentation so they meet the buyer team and understand the post-close opportunity. Expect the buyer to ask for a written associate retention plan and may tie a portion of consideration to associate retention milestones.

Should I sell my building with the practice, or hold it back and lease to the new owner?

Holding the real estate separately is usually the higher-value path. Move it into a separate LLC at fair market value triple-net rent to the operating practice. This often lifts the implied EBITDA multiple on the operating practice by 0.5x to 1.0x because the buyer is not forced to underwrite real estate exposure (Plante Moran sale-leaseback primer; Northmarq; W. P. Carey). You then have three options at close: assign the lease to the buyer, sell the real estate to the buyer at appraised value, or execute a sale-leaseback with a triple-net medical-office REIT investor at the same time as the operating practice sale. The sale-leaseback path can convert close to 100% of property market value as cash, vs. 70% to 80% LTV via traditional refinancing. Veterinary medical-office properties typically trade at 6.5% to 8% cap rates in growth metros, which is often a richer monetization on the real estate than the operating-business multiple alone.

What to Do Next

The veterinary practice owners who get the top-quartile multiple in the bifurcated 2026 market all do the same three things. They start preparing 24 to 36 months before they want to be out, knowing that the levers worth the most (owner clinical step-down, wellness-plan ARR, associate hiring, AAHA accreditation, cloud PIMS migration) all need 12+ months of clean data behind them. They get the practice manager / GM in place 12+ months pre-sale and run the two-week unplugged owner vacation as the stress test before any buyer sees a CIM. And they invest in a sell-side QoE that pre-empts the wellness-plan deferred-revenue argument the buyer’s accountant is about to raise.

The market is honest right now in a way it has not been since before 2021. Top-quartile A+ hospitals are still clearing 14x or higher and Mission Pet Health printed 17x to 18x on the largest vet platform deal of the cycle. At the same time, average sub-scale demand-only practices have compressed into a 4x to 7x band that did not exist three years ago. Visit volume is structurally soft and the buyer scrutiny on price-vs-volume growth is the sharpest it has ever been. The prep work is what determines which band you end up in.

If you are 12+ months from a potential exit and want a structured pre-sale optimization roadmap, CT Acquisitions has veterinary operations specialists in our partner network who run multi-quarter prep engagements covering associate hiring plans, wellness-plan rollouts, KPI infrastructure builds, AAHA accreditation, and the full compliance scrub. If you are 6 to 12 months out and ready to start the sell-side process, our M&A advisory team runs the buyer outreach across Mars, NVA, Ethos, Mission Pet Health, VetCor, AmeriVet, VPP, Western Vet Partners, MedVet, VEG, and the rest of the active 2026 platforms. Buyers pay our fee, not you. Either way, the first 30 minutes are free.